期刊
JOURNAL OF INFECTIOUS DISEASES
卷 215, 期 8, 页码 1255-1263出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jix099
关键词
HIV; vaccine; RV144; prime-boost
资金
- US Army Medical Research and Materiel Command (Military Infectious Diseases Research Program) [W81XWH-11-2-0174, W81XWH-07-2-0067]
- Henry M. Jackson Foundation for the Advancement of Military Medicine)
- National Institute of Allergy and Infectious Disease [Y1-AI-2642-12]
- National Institute of Allergy and Infectious Disease (US Army Medical Research and Materiel Command)
- National Institute of Allergy and Infectious Disease (F31 fellowship)
- Bill & Melinda Gates Foundation (CAVIMC) [OPP1032144, OPP1146996]
- Ministry of Health & Welfare (MHOW), Republic of Korea [1345244495] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Background. The RV144 ALVAC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year, waning to 31.2% after 3.5 years. We hypothesized that additional vaccinations might augment immune correlates of protection. Methods. In a randomized placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine recipients, we evaluated 2 additional boosts, given 6-8 years since RV144 vaccination, for safety and immunogenicity, at weeks 0 and 24. Study groups 1-3 received ALVAC-HIV+AIDSVAX B/E, AIDSVAX B/E, and ALVAC-HIV, respectively, or placebo. Results. Vaccines were well tolerated. For groups 1 and 2, plasma immunoglobulin (Ig) G, IgA, and neutralizing antibody responses at week 2 were all significantly higher than 2 weeks after the last RV144 vaccination. IgG titers against glycoprotein (gp) 70V1V2 92TH023 increased 14-fold compared with 2 weeks after the last RV144 vaccination ( 14 069 vs 999; P <.001). Groups 1 and 2 did not differ significantly from each other, whereas group 3 was similar to placebo recipients. Responses in groups 1 and 2 declined by week 24 but were boosted by the second vaccination, albeit at lower magnitude than for week 2. Conclusions. In RV144 vaccinees, AIDSVAX B/E with or without ALVAC-HIV 6-8 years after initial vaccination generated higher humoral responses than after RV144, but these responses were short-lived, and their magnitude did not increase with subsequent boost.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据